"Spending on psych drugs Up 150%, Diagnosis of Depression 25% Inflated"...

"Spending on psych drugs Up 150%, Diagnosis of Depression 25% Inflated"...

Joined: January 1st, 1970, 12:00 am

April 4th, 2007, 2:02 pm #1


http://ahrp.blogspot.com/2007/04/spending-on-psych-drugs-up-150.html

<H3 class=post-title>Spending on psych drugs Up 150% Diagnosis of Depression 25% Inflated</H3>
<DIV class=post-body>
<DIV>According to a new report by the U.S. Agency for Healthcare Research and Quality (AHR&Q), U.S. spending on psychotropic drugs climbed from $7.9 billion in 1997 to $20 billion in 2004--that's an increase of 150% in just seven years. After years of marketing, these drugs now carry the most severe Black Box label warnings.

The sharpest rise in spending was for antipsychotic drugs (a.k.a. neuroleptics) which were approved only for use in managing schizophrenia and bipolar disorder--together these account for 2% of the population. Yet total purchases to treat these conditions more than tripled -- from $1.3 billion to $4.1 billion.

<STRONG>These second generation neuroleptics are the most toxic of all psychotropic drugs: they interfere with normal metabolic, endocrine, and cardiovascular function. Their mechanisms of action induce debilitating chronic disease--including hyperglycemia, insulin-resistant diabetes, stroke and heart attacks.
</STRONG>
<STRONG>Antidepressants, the AHR&Q study found, accounted for more than half ($12.1 billion) of the total expenditures for psychotherapies in 2004. These drugs trigger psychosis and antisocial aggressive, violent, manic behavior posing threat of harm to self (suicide) and others (homicide). </STRONG>The drugs have not proven a clinical benefit. Instead, they have worsened the symptoms for which they were initially prescribed, such as stress or difficulty falling asleep. Antidepressants and antipsychotics have been shown to undermine mental and physical health in some persons for whom they were prescribed.<STRONG> The drugs disrupt normal mental and physiological functions and have been shown to induce psychosis, hallucinations, and suicidal behavior.
</STRONG>
Why, people may ask, are these drugs so widely prescribed and how did they become blockbuster sellers? The answers are found in the unintended consequence of ill-advised laws that gave drug manufacturers too much influence on government policy
[Link] and in documents unearthed in litigation and in the subjective non-empirical diagnostic criteria. Company documents show that drug companies have engaged in aggressive marketing of these drugs despite knowledge of their hazardous effects--and they have actively influenced the diagnostic prescribing criteria.

<IMG height=204 hspace=10 src="http://www.thejabberwock.org/blog/dsm1.png" width=226 align=left vspace=10 border=0>A just released report in the Archives of General Psychiatry by investigators from New York University, Columbia University, University of Pennsylvania, and Rutgers, delivers a major blow to the validity of psychiatry's diagnostic criteria. The authors examined the distinctions used for diagnosing "major depression" and found that 25% of those "diagnosed" with "major depression" in accordance with the criteria set forth in psychiatry's diagnostic guide-the DSM -IV--are not clinically depressed. They are responding normally to traumatic life events.

The Washington Post correctly notes, "The finding could have far-reaching consequences for the diagnosis of depression, the growing use of symptom checklists to identify those who may be depressed, and the $12 billion-a-year U.S. market for antidepressant drugs." The most aggressive of these diagnostic chekclists is TeenScreen with its 84% false-positive misidentification rate.

The DSM-IV is a product under the influence of industry as has been documented by Drs. Lisa Cosgrove and Sheldon Krimsky: [Link] and [Link]

Further evidence of corruption behind the spiraling sales statistics for psychotropic drugs is documented in company reports and memos. Alex Berenson of The New York Times disclosed the content of Eli Lilly Zyprexa documents showing that the company concealed the evidence of harm produced from physicians and the public [Link]. Instead, the airwaves were flooded with false and misleading advertisements whose claims are contradicted by the evidence of the drugs' safety hazards. [Link] The FDA failed to intervene.

Industry, in collaboration (i.e. collusion) with influential mental health professionals and industry funded "advocacy" groups--including the American Psychiatric Association, the National Institute of Mental Health, Mental Health America, the American Academy of Child and Adolescent Psychiatry, the National Alliance for Mental Illness--succeeded in getting these drugs listed as first line treatments in psychiatry's prescribing guidelines hospital formularies.

<STRONG>TMAP--the Texas Medication Algorithm Project--is Big Pharma's psychotropic drug sweepstakes.</STRONG> [Link]

The academic architects of TMAP and TMAP promoters in state government and academia, should be questioned under oath to determine how the flow of cash from industry influenced the formulation and adoption of TMAP by numerous state mental health departments.

<STRONG>Of note: New York Governor Eliot Spitzer appears to have completely reversed his informed legal action in the public interest when, as Attorney General, he filed suit against GlaxoSmithKline to persuade drug companies to disclose the facts about drug safety to the public. As a newly elected governor, he made a political appointment to appease the mental health drug industry cartel.</STRONG>

Eliot Spitzer appointed Michael Hogan, PhD, Commissioner of NYS Office of Mental Health. Dr. Hogan was a pivotal promoter of TMAP and the expanded use of the most expensive psychotropic drugs when he headed the Ohio Office of Mental Health, and chaired the President's New Freedom Commission on Mental Health which gave TMAP a federal seal of approval. Dr. Hogan also serves on the National Advisory Council of TeenScreen, the other market expansion scheme. [Link]





</DIV></DIV>
Quote
Like
Share

Joined: January 1st, 1970, 12:00 am

April 4th, 2007, 2:04 pm #2

<STRONG>"These second generation neuroleptics are the most toxic of all psychotropic drugs: they interfere with normal metabolic, endocrine, and cardiovascular function. Their mechanisms of action induce debilitating chronic disease--including hyperglycemia, insulin-resistant diabetes, stroke and heart attacks."</STRONG>
Quote
Like
Share

Joined: January 1st, 1970, 12:00 am

April 4th, 2007, 2:13 pm #3

"<STRONG>Of note: New York Governor Eliot Spitzer appears to have completely reversed his informed legal action in the public interest when, as Attorney General, he filed suit against GlaxoSmithKline to persuade drug companies to disclose the facts about drug safety to the public. As a newly elected governor, he made a political appointment to appease the mental health drug industry cartel.</STRONG>

Eliot Spitzer appointed Michael Hogan, PhD, Commissioner of NYS Office of Mental Health. Dr. Hogan was a pivotal promoter of TMAP and the expanded use of the most expensive psychotropic drugs when he headed the Ohio Office of Mental Health, and chaired the President's New Freedom Commission on Mental Health which gave TMAP a federal seal of approval. Dr. Hogan also serves on the National Advisory Council of TeenScreen, the other market expansion scheme. [Link]"
Quote
Like
Share

Joined: January 1st, 1970, 12:00 am

April 4th, 2007, 2:21 pm #4


"The total number of antidepressant purchases skyrocketed from 88.3 million in 1997 to 161.2 million in 2004, and the number of people who reported making such purchases increased from 15.3 million to 24.8 million.


The study found that the sharpest rise in spending was for antipsychotic agents, or medications used to manage schizophrenia, bipolar disorder and other psychotic disorders. Total purchases to treat these conditions more than tripled -- from $1.3 billion to $4.1 billion.


Likewise, total expenditures for central nervous system stimulants to treat pain and control seizures nearly tripled during the seven years --from $600 million to $1.7 billion. The number of people who said they bought at least one of these drugs increased from 2.1 million to 3.3 million, and the total number of purchases of such prescriptions swelled from 11.8 million to 19.7 million.


Meanwhile, purchases of sedatives, hypnotics and medicines to ease anxiety nearly doubled from $900 million to $2.1 billion. Total purchases of those drugs climbed from 24.5 million to 39 million, and the number of people who said they bought at least one of those drugs surged from 5.4 million to nearly 8 million."

Quote
Like
Share

Joined: January 1st, 1970, 12:00 am

April 4th, 2007, 2:25 pm #5

"<STRONG>Of note: New York Governor Eliot Spitzer appears to have completely reversed his informed legal action in the public interest when, as Attorney General, he filed suit against GlaxoSmithKline to persuade drug companies to disclose the facts about drug safety to the public. As a newly elected governor, he made a political appointment to appease the mental health drug industry cartel.</STRONG>

Eliot Spitzer appointed Michael Hogan, PhD, Commissioner of NYS Office of Mental Health. Dr. Hogan was a pivotal promoter of TMAP and the expanded use of the most expensive psychotropic drugs when he headed the Ohio Office of Mental Health, and chaired the President's New Freedom Commission on Mental Health which gave TMAP a federal seal of approval. Dr. Hogan also serves on the National Advisory Council of TeenScreen, the other market expansion scheme. [Link]"
<STRONG>Of note: New York Governor Eliot Spitzer appears to have completely reversed his informed legal action in the public interest when, as Attorney General, he filed suit against GlaxoSmithKline to persuade drug companies to disclose the facts about drug safety to the public. As a newly elected governor, he made a political appointment to appease the mental health drug industry cartel.</STRONG>

Eliot Spitzer appointed Michael Hogan, PhD, Commissioner of NYS Office of Mental Health. Dr. Hogan was a pivotal promoter of TMAP and the expanded use of the most expensive psychotropic drugs when he headed the Ohio Office of Mental Health, and chaired the President's New Freedom Commission on Mental Health which gave TMAP a federal seal of approval. Dr. Hogan also serves on the National Advisory Council of TeenScreen, the other market expansion scheme. [Link]"
<!-- google_ad_section_end -->
Quote
Like
Share

Joined: January 1st, 1970, 12:00 am

April 4th, 2007, 4:35 pm #6

http://ahrp.blogspot.com/2007/04/spending-on-psych-drugs-up-150.html

<H3 class=post-title>Spending on psych drugs Up 150% Diagnosis of Depression 25% Inflated</H3>
<DIV class=post-body>
<DIV>According to a new report by the U.S. Agency for Healthcare Research and Quality (AHR&Q), U.S. spending on psychotropic drugs climbed from $7.9 billion in 1997 to $20 billion in 2004--that's an increase of 150% in just seven years. After years of marketing, these drugs now carry the most severe Black Box label warnings.

The sharpest rise in spending was for antipsychotic drugs (a.k.a. neuroleptics) which were approved only for use in managing schizophrenia and bipolar disorder--together these account for 2% of the population. Yet total purchases to treat these conditions more than tripled -- from $1.3 billion to $4.1 billion.

<STRONG>These second generation neuroleptics are the most toxic of all psychotropic drugs: they interfere with normal metabolic, endocrine, and cardiovascular function. Their mechanisms of action induce debilitating chronic disease--including hyperglycemia, insulin-resistant diabetes, stroke and heart attacks.
</STRONG>
<STRONG>Antidepressants, the AHR&Q study found, accounted for more than half ($12.1 billion) of the total expenditures for psychotherapies in 2004. These drugs trigger psychosis and antisocial aggressive, violent, manic behavior posing threat of harm to self (suicide) and others (homicide). </STRONG>The drugs have not proven a clinical benefit. Instead, they have worsened the symptoms for which they were initially prescribed, such as stress or difficulty falling asleep. Antidepressants and antipsychotics have been shown to undermine mental and physical health in some persons for whom they were prescribed.<STRONG> The drugs disrupt normal mental and physiological functions and have been shown to induce psychosis, hallucinations, and suicidal behavior.
</STRONG>
Why, people may ask, are these drugs so widely prescribed and how did they become blockbuster sellers? The answers are found in the unintended consequence of ill-advised laws that gave drug manufacturers too much influence on government policy
[Link] and in documents unearthed in litigation and in the subjective non-empirical diagnostic criteria. Company documents show that drug companies have engaged in aggressive marketing of these drugs despite knowledge of their hazardous effects--and they have actively influenced the diagnostic prescribing criteria.

<IMG height=204 hspace=10 src="http://www.thejabberwock.org/blog/dsm1.png" width=226 align=left vspace=10 border=0>A just released report in the Archives of General Psychiatry by investigators from New York University, Columbia University, University of Pennsylvania, and Rutgers, delivers a major blow to the validity of psychiatry's diagnostic criteria. The authors examined the distinctions used for diagnosing "major depression" and found that 25% of those "diagnosed" with "major depression" in accordance with the criteria set forth in psychiatry's diagnostic guide-the DSM -IV--are not clinically depressed. They are responding normally to traumatic life events.

The Washington Post correctly notes, "The finding could have far-reaching consequences for the diagnosis of depression, the growing use of symptom checklists to identify those who may be depressed, and the $12 billion-a-year U.S. market for antidepressant drugs." The most aggressive of these diagnostic chekclists is TeenScreen with its 84% false-positive misidentification rate.

The DSM-IV is a product under the influence of industry as has been documented by Drs. Lisa Cosgrove and Sheldon Krimsky: [Link] and [Link]

Further evidence of corruption behind the spiraling sales statistics for psychotropic drugs is documented in company reports and memos. Alex Berenson of The New York Times disclosed the content of Eli Lilly Zyprexa documents showing that the company concealed the evidence of harm produced from physicians and the public [Link]. Instead, the airwaves were flooded with false and misleading advertisements whose claims are contradicted by the evidence of the drugs' safety hazards. [Link] The FDA failed to intervene.

Industry, in collaboration (i.e. collusion) with influential mental health professionals and industry funded "advocacy" groups--including the American Psychiatric Association, the National Institute of Mental Health, Mental Health America, the American Academy of Child and Adolescent Psychiatry, the National Alliance for Mental Illness--succeeded in getting these drugs listed as first line treatments in psychiatry's prescribing guidelines hospital formularies.

<STRONG>TMAP--the Texas Medication Algorithm Project--is Big Pharma's psychotropic drug sweepstakes.</STRONG> [Link]

The academic architects of TMAP and TMAP promoters in state government and academia, should be questioned under oath to determine how the flow of cash from industry influenced the formulation and adoption of TMAP by numerous state mental health departments.

<STRONG>Of note: New York Governor Eliot Spitzer appears to have completely reversed his informed legal action in the public interest when, as Attorney General, he filed suit against GlaxoSmithKline to persuade drug companies to disclose the facts about drug safety to the public. As a newly elected governor, he made a political appointment to appease the mental health drug industry cartel.</STRONG>

Eliot Spitzer appointed Michael Hogan, PhD, Commissioner of NYS Office of Mental Health. Dr. Hogan was a pivotal promoter of TMAP and the expanded use of the most expensive psychotropic drugs when he headed the Ohio Office of Mental Health, and chaired the President's New Freedom Commission on Mental Health which gave TMAP a federal seal of approval. Dr. Hogan also serves on the National Advisory Council of TeenScreen, the other market expansion scheme. [Link]





</DIV></DIV>
<FONT class=Arial10 face=Arial>Probably have this article as its dated last December, but I wonder how much of that profit has been made by extending prescriptions&nbsp;to children and&nbsp;helpless babies.</FONT>

<FONT class=Arial10 face=Arial>
http://www.informationliberation.com/?id=18801


<TABLE cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR>
<TD>
Doctors prescribing antidepressants, antipsychotic medications to infants under the age of one, says psychiatrist
<FONT class=Arial12 face=Arial color=black><SPAN id=ga>
<SCRIPT type=text/javascript><!--
google_ad_client = "pub-3923740223021058";
google_alternate_ad_url = "http://www.informationliberation.com/google_adsense_script.html";
google_ad_width = 300;
google_ad_height = 250;
google_ad_format = "300x250_as";
google_ad_type = "text_image";
google_ad_channel ="7731124324";
google_color_border = "FFFFFF";
google_color_bg = "FFFFFF";
google_color_link = "3d6299";
google_color_url = "333333";
google_color_text = "333333";
//--></SCRIPT>

<SCRIPT src="http://pagead2.googlesyndication.com/pagead/show_ads.js" type=text/javascript>
</SCRIPT>
<IFRAME name=google_ads_frame marginWidth=0 marginHeight=0 src="http://pagead2.googlesyndication.com/pagead/ads?client=ca-pub-3923740223021058&dt=1175701681531&lmt=1175701681&alternate_ad_url=http%3A%2F%2Fwww.informationliberation.com%2Fgoogle_adsense_script.html&format=300x250_as&output=html&channel=7731124324&url=http%3A%2F%2Fwww.informationliberation.com%2F%3Fid%3D18801&color_bg=FFFFFF&color_text=333333&color_link=3d6299&color_url=333333&color_border=FFFFFF&ad_type=text_image&cc=99&u_h=768&u_w=1024&u_ah=737&u_aw=1024&u_cd=32&u_tz=60&u_his=2&u_java=true" frameBorder=0 width=0 scrolling=no height=0 allowTransparency></IFRAME></SPAN>By Ben Kage

According to<STRONG> Dr. Yolande Lucire</STRONG>, a forensic psychicatrist based in New South Wales, Australia, doctors are giving children younger than 1 year of age prescriptions for atypical antipsychotics -- a class of narcotics used to treat schizophrenia, bipolar mania, psychotic agitation and other similar conditions.

In an email to Alliance for Human Research Protection President Vera Hassner Sharav, Lucire, published on the AHRP web site, Lucire says that she is taking kids under her care off of atypical antipsychotic medications.

"Not one met the criteria for schizophrenia when these drugs were started," Lucire says in the email. She added that the patients "often got psychosis on antidepressants given for anxiety, or substance induced disorders."

While Australia is the second largest consumer of psychotropic drugs, according to Sharav, it still takes a back seat to the United States. Sharav reports that the alliance obtained the New Jersey Medicaid record of psychotropic drugs prescribed to more than 39,000 children aged 0 to 18. They found that most of the drugs were prescribed for off label use, i.e. a condition for which the drug was not originally designed. Also, the reports indicated that the antidepressant Effexor and antispsychotics such as Risperdal are being prescribed to children younger than 1; antipsychotics like Seroquel are being prescribed to 2-year-olds; and .05 milligram to 20 milligram doses of the antipsychotic Risperdal are being prescribed to 3-year-olds.

"Is this what <STRONG>'leave no child behind' </STRONG>is all about?" said Sharav on the AHRP web site.

Predictably, the children on these drugs (and some who have stopped taking them) are displaying horrifying side effects. Lucire reports patients who are "punch drunk with dementia," occasionally psychotic and showing signs of akathisia, or an inability to sit still. Additionally, Lucire noted she had observed hyperactivity, aggression or hostility, and cognitive impairment, along with tardive dyskinesia, a neurological disorder brought on by long-term use of, or high-dose exposure to, drugs that block dopamine receptors. Repetitive, involuntary and purposeless movements characterize the condition.

If these side effects were not disturbing enough, a Duke University study suggested that the drug class might be connected to pancreatitis. Worse, some patients -- adults and children -- are reporting cases of type 1 and type 2 diabetes, as well as hyperglycemia in connection with use of atypical antipsychotics, with some cases ending in death. The condition seemed to affect mostly young, male patients.

The link between diabetes and the atypical antipsychotics is thought to stem from the weight gain reported by some users of the drugs. Some patients have said they gained as much as 65 pounds, and subsequently developed diabetes or glucose abnormalities. This has caught the attention of the FDA, which is waiting on a Veterans Administration analysis before deciding whether to put a warning label on the drugs, according to a spokesperson. Some atypical antipsychotics already carry such labels in Japan and Europe..."</FONT>

<FONT class=Arial12 face=Arial color=black></FONT>&nbsp;

&nbsp;

Amazing the FDA can't work it out&nbsp;a bit faster.&nbsp; Also amazing that they let the industry market and expand the use of such dodgy drugs.&nbsp; But I suppose it pays them to not use any integrity or even common sense.&nbsp;

</TD></TR></TBODY></TABLE>



</FONT>
Quote
Like
Share